We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Aba6.0
Abaloparatide Research
Mostly mechanism / observational
69 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Abaloparatide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2015–2026 with a typical study size of 1,469 participants.
Based on 69 studies · 21 meta-analyses · 31 RCTs · 30,951 total participants
Confidence
High confidence
By outcome
Bone density & anabolic bone formationIn the ACTIVE phase-3 RCT new vertebral fractures fell ~86% vs placebo over 18 months; nonvertebral fractures also reduced; spine/hip/femoral-neck BMD rose significantly · 6-18 months
Mostly mechanism / observational61 studies
Fracture & skeletal endpoints
Mostly mechanism / observational13 studies
Safety profile
Mostly mechanism / observational7 studies
Active research area
39 studies in the last 5 years · Latest meta-analysis: 2025
201520202026
1Meta-Analysis2022
Shen J, Ke Z, Dong S, Lv M, Yuan Y, Song L · Med Sci Monit (2022)
Xu F, Wang Y, Zhu X. · Clinical therapeutics (2024)
The incidence of vertebral fracture was lower in the abaloparatide group than in the control group (risk ratio, 0.13; 95% CI, 0.06-0.26; I 2 = 0%).
There was no significant difference in the incidence of adverse events between the abaloparatide and the placebo groups (risk ratio, 1.03; 95% CI, 0.99-1.06; I 2 = 0%).
Implications Abaloparatide has a protective effect on women with postmenopausal osteoporosis.